Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Non-Hodgkin × danvatirsen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Lymphoma, Large B-Cell, Diffuse 2 Turcot syndrome 1 Squamous Cell Carcinoma of Head and Neck 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Muscle Invasive Bladder Cancer 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Gastrointestinal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Hepatocellular 1 Ascites 1 Advanced Solid Tumours 1 Advanced Solid Malignancies 1

Interventions

Rituximab 305 Cyclophosphamide 287 Etoposide 125 fludarabine phosphate 124 Peripheral Blood Stem Cell Transplantation 107 fludarabine 104 Filgrastim 103 Melphalan 91 Mycophenolic Acid 87 Whole-Body Irradiation 80 Vincristine 80 Cytarabine 77 Busulfan 77 Doxorubicin 71 Radiotherapy 70 Prednisone 67 Cyclosporine 67 Tacrolimus 64 Bendamustine Hydrochloride 61 Methotrexate 56 Granulocyte Colony-Stimulating Factor 56 Antilymphocyte Serum 50 Carmustine 48 Dexamethasone 44 Gemcitabine 42 Lenalidomide 41 venetoclax 39 Bortezomib 35 obinutuzumab 33 ibritumomab tiuxetan 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03527147 2022-08-15

PRISM

Acerta Pharma BV

Phase 1 Completed

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡